IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
City of Hope Medical Center
Roswell Park Cancer Institute
Beijing Biotech
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Mayo Clinic
Essen Biotech
M.D. Anderson Cancer Center
Baylor College of Medicine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chinese PLA General Hospital
BioEclipse Therapeutics
Fate Therapeutics
Fate Therapeutics
The Affiliated Hospital of Xuzhou Medical University
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Third Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Wenzhou Medical University
Baylor College of Medicine
National Cancer Institute, Naples
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xinqiao Hospital of Chongqing
City of Hope Medical Center
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)